Latest Research And Development News

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Biotron Limited has successfully closed its fully subscribed rights issue, raising $1.52 million, and completed the acquisition of Sedarex Limited, positioning itself for growth in its diversified biotech portfolio.

Stakk Limited has reported a robust Q2FY26 with record cash receipts and a fortified $15.1 million cash reserve, setting the stage for breakeven in CY26 amid strong Tier-1 client momentum.

TradeWindow reports solid growth in recurring revenue and average revenue per customer but lowers its FY26 trading revenue guidance due to softer transactional volumes in Q3.

BluGlass Limited has extended its contract with the U.S. Department of War by A$1.05 million and appointed a refreshed Board to accelerate its commercial growth in visible laser technology. The company is advancing its GaN laser portfolio amid a US$100 million project pipeline and ongoing R&D investments.

Latrobe Magnesium has resolved a critical manufacturing defect at its Demonstration Plant, enabling Magnesium Oxide production to resume, while securing key financial support for its commercial expansion plans.

Audio Pixels has validated a major technical milestone for its digital MEMS speaker array and raised $1.25 million through convertible notes, while securing a $6 million funding commitment to support ongoing development amid continued ASX trading suspension.

Papyrus Australia has taken a significant step towards commercialisation with a $4.2 million supply contract and the near completion of its Adelaide Rapid Prototyping and R&D Facility.

CONNEQT Health has reported a remarkable surge in Pulse device sales, exceeding 200% growth quarter-on-quarter, while advancing its transition to a recurring revenue model through enterprise contracts and consumer subscriptions.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Beetaloo Energy Australia Limited reported a solid cash position of $17.96 million at the end of December 2025, supported by $6.8 million in unused financing facilities. The company’s liquidity covers approximately 2.6 quarters of current cash outflows, positioning it well as it awaits the activation of a new $30 million infrastructure facility.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.